\n Data tracked by StockTitan Argus<\/a> (15 min delayed). Upgrade to Silver<\/a> for real-time data. \n <\/p>\n
\n Dosing frequency
\n once-weekly<\/p>\n
ARAKODA malaria prevention regimen for international travelers<\/p>\n
\n Partnership start date
\n April 2, 2026<\/p>\n
Runway Health telehealth partnership commencement<\/p>\n
\n $2.00
\n Last Close\n <\/p>\n
\n Volume
\n Volume 498,626 is about 2.77x the 20-day average of 179,807, indicating elevated trading interest ahead of this news.<\/p>\n
high<\/p>\n
\n Technical
\n Shares at $2.00 are trading below the 200-day MA of $6.56, after a steep decline from the $24.00 52-week high.\n <\/p>\n
Momentum scanner shows only 1 peer (ADTX) moving, down 8.90%, while the scanner flags SXTP\u2019s direction as up. Other listed biotech peers show a mix of modest gains and losses, suggesting today\u2019s setup is more stock-specific than sector-driven.<\/p>\n
Date
\n Event
\n Sentiment
\n Move
\n Catalyst<\/p>\n
Jan 15<\/p>\n
Reverse stock split<\/a><\/p>\n Negative<\/p>\n -2.4%<\/p>\n Announced 1-for-4 reverse split to regain Nasdaq bid compliance.<\/p>\n Dec 29<\/p>\n Clinical study data<\/a><\/p>\n Positive<\/p>\n -20.6%<\/p>\n Reported 24% Babesia infection rate supporting B-FREE babesiosis study.<\/p>\n Dec 11<\/p>\n Commercial expansion<\/a><\/p>\n Positive<\/p>\n -7.0%<\/p>\n Planned 2026 ARAKODA sales force expansion and new GoodRx partnership.<\/p>\n Nov 21<\/p>\n Trial enrollment start<\/a><\/p>\n Positive<\/p>\n +0.0%<\/p>\n Opened central site to enroll up to 100 B-FREE babesiosis patients.<\/p>\n Nov 13<\/p>\n Q3 2025 earnings<\/a><\/p>\n Negative<\/p>\n -5.4%<\/p>\n Q3 2025 showed higher revenue but gross loss and $2.44M net loss.<\/p>\n Pattern Detected<\/p>\n Recent history shows SXTP shares often lag or sell off on operational and clinical positives, while more dilutive or loss-focused items have seen moves align with the negative tone.<\/p>\n Recent Company History<\/p>\n Over the past few months, 60 Degrees Pharmaceuticals has focused on strengthening ARAKODA\u2019s commercial footprint and advancing babesiosis research. Key steps included opening the B-FREE Phase 2 site at Mount Sinai on Nov 21, 2025 and planning expanded ARAKODA sales and marketing for 2026. Financial updates on Nov 13, 2025 highlighted rising revenue but ongoing losses and higher operating expenses. A reverse stock split effective Jan 20, 2026 aimed at Nasdaq compliance. Today\u2019s Runway Health partnership fits the ongoing strategy to broaden ARAKODA access for travelers.<\/p>\n \n The stock is surging +266.5% following this news. A strong positive reaction aligns with SXTP\u2019s strategy of monetizing ARAKODA through broader access. The Runway Health partnership adds a telehealth channel that fits prior 2026 marketing plans. However, past news often saw selling even on positives, and the stock trades far below its $24.00 52-week high and $6.56 200-day MA. Investors would need to weigh execution risk and past loss levels when assessing sustainability.\n <\/p>\n vector-borne disease<\/p>\n medical<\/p>\n “a pharmaceutical company focused on developing new medicines for vector-borne disease”<\/p>\n An illness spread when an infected living carrier \u2014 such as a mosquito, tick or flea \u2014 carries a pathogen from one person or animal to another, like a delivery service moving a package between houses. Investors care because outbreaks can change demand for vaccines, tests, treatments and pest control, disrupt travel, agriculture and labor, and alter insurance and healthcare costs, affecting company revenues and market risk across multiple sectors.<\/p>\n telehealth<\/p>\n technical<\/p>\n “Runway Health is a direct-to-patient telehealth platform that enables adults”<\/p>\n Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies\u2014similar to how online banking changed financial services\u2014while also exposing businesses to reimbursement and regulatory shifts.<\/p>\n AI-generated analysis. Not financial advice.<\/p>\n
01\/22\/2026 – 08:01 AM<\/p>\n Partnership adds a travel-focused consumer telehealth platform to the ARAKODA\u00ae marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the worldARAKODA is the only FDA-approved, broad spectrum, once-weekly malaria prevention option for international travelers <\/p>\n WASHINGTON, Jan. 22, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc.<\/a>\u00a0(NASDAQ: SXTP<\/a>; SXTPW<\/a>) (\u201c60 Degrees Pharma\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with Runway Health to expand pre-departure access to ARAKODA\u00ae (tafenoquine) for prevention of malaria among international travelers through the Runway Health travel medicine platform.<\/p>\n ARAKODA is the only broad spectrum, once-weekly prescription malaria prevention on the U.S. market.<\/p>\n Runway Health is a direct-to-patient telehealth platform that enables adults to access physician-led online consultations before traveling to regions of the world where certain illnesses, including malaria, may be prevalent. If prescribed, seamless home delivery of medication arrives before departure.<\/p>\n Malaria, which is caused by the bite of the Anopheles mosquito, is one of the most serious, life-threatening infectious diseases in the world. It is a constant threat to those living in malaria-endemic regions and to international travelers to those areas. If left untreated, it can progress to severe malaria, which is often fatal.<\/p>\n The partnership with Runway Health commences April 2, 2026. It adds a new platform to the 60 Degrees Pharma ARAKODA marketing strategy, where eligible users can match their travel itinerary with a personalized medical treatment plan designed by a U.S. licensed healthcare provider.<\/p>\n About ARAKODA\u00a0(tafenoquine)<\/p>\n Tafenoquine\u00a0is approved for malaria prophylaxis in\u00a0the United States\u00a0under the product name ARAKODA\u00ae. The safety of the approved regimen of\u00a0tafenoquine\u00a0for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for durations of up to six months.<\/p>\n Tafenoquine\u00a0was discovered by\u00a0Walter Reed Army Institute of Research,\u00a0and the current study was funded by the United States Army Medical & Materiel Activity.\u00a0Tafenoquine\u00a0was approved for malaria prophylaxis in 2018 in\u00a0the United States\u00a0as ARAKODA\u00ae\u00a0and in\u00a0Australia\u00a0as KODATEF\u00ae. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug.<\/p>\n According to the\u00a0Centers for Disease Control and Prevention, the long terminal half-life of\u00a0tafenoquine, which is approximately 16 days, may offer potential advantages in less-frequent dosing for prophylaxis for malaria.\u00a0ARAKODA\u00ae\u00a0is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA\u00ae\u00a02 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel.<\/p>\n ARAKODA\u00ae\u00a0(tafenoquine) Important Safety Information<\/p>\n ARAKODA\u00ae\u00a0is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older.<\/p>\n Contraindications<\/p>\n ARAKODA\u00ae\u00a0should not be administered to:<\/p>\n Glucose-6-phosphate dehydrogenase (\u201cG6PD\u201d) deficiency or unknown G6PD status;Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or ifG6PD status is unknown;Patients with a history of psychotic disorders or current psychotic symptoms; orKnown hypersensitivity reactions to\u00a0tafenoquine, other 8-aminoquinolines, or any component of ARAKODA\u00ae. <\/p>\n Warnings and Precautions<\/p>\n Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA\u00ae\u00a0due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis.<\/p>\n G6PD Deficiency in Pregnancy or Lactation: ARAKODA\u00ae\u00a0may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA\u00ae\u00a0is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA\u00ae\u00a0through breast milk. Check infant\u2019s G6PD status before breastfeeding begins.<\/p>\n Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur.<\/p>\n Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA\u00ae\u00a0therapy and evaluation by a mental health professional as soon as possible.<\/p>\n Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA\u00ae. If hypersensitivity reactions occur, institute appropriate therapy.<\/p>\n Delayed Adverse Reactions: Due to the long half-life of ARAKODA\u00ae\u00a0(approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and\/or duration.<\/p>\n Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase, motion sickness, insomnia, depression, abnormal dreams, and anxiety.<\/p>\n Drug Interactions<\/p>\n Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters.<\/p>\n Use in Specific Populations<\/p>\n Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA\u00ae. To report SUSPECTED ADVERSE REACTIONS, contact\u00a060 Degrees Pharmaceuticals, Inc.\u00a0at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or\u00a0www.fda.gov\/medwatch<\/a>. The full prescribing information of ARAKODA\u00ae\u00a0is located\u00a0here<\/a>.<\/p>\n About\u00a060 Degrees Pharmaceuticals, Inc. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management\u2019s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.<\/p>\n Cautionary Note Regarding Forward-Looking Statements<\/p>\n This press release may contain \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the\u00a0U.S.\u00a0Private Securities Litigation Reform Act of 1995. Forward\u2010looking statements reflect the current view about future events. When used in this press release, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cfuture,\u201d \u201cintend,\u201d \u201cplan,\u201d or the negative of these terms and similar expressions, as they relate to us or our management, identify forward\u2010looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,\u00a0expectations\u00a0and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for\u00a0tafenoquine\u00a0(ARAKODA\u00ae or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market.\u00a0More detailed information about the Company and the risk factors that may affect the realization of forward- looking statements is set forth in the Company\u2019s filings with the\u00a0Securities and Exchange Commission\u00a0(\u201cSEC\u201d), including the information contained in our Annual Report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0April 1, 2024, and our subsequent\u00a0SEC\u00a0filings. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s website at\u00a0www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company\u2019s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n Media Contact:
\n
\n
\n
\n
\n
\n
<\/p>\n
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved\u00a0U.S. Food and Drug Administration\u00a0approval of Its lead product, ARAKODA\u00ae\u00a0(tafenoquine), for malaria prevention, in 2018. ARAKODA is commercially available in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0also collaborates with prominent research and academic organizations in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0is headquartered in\u00a0Washington, D.C., with a subsidiary in\u00a0Australia. Learn more at\u00a0www.60degreespharma.com<\/a>.<\/p>\n
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com<\/a>
(484) 667-6330<\/p>\n
![\"\"](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/01\/1769093527_919_ti.gif\"\/)
![\"\"](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/01\/Sixty-Degrees-Pharmaceuticals.png\")
<\/p>\n